Ocrevus Use Rises for New RRMS Patients, Drops Among PPMS Patients

Home Forums MS Medications Ocrevus Use Rises for New RRMS Patients, Drops Among PPMS Patients
  • This topic is empty.
Viewing 0 reply threads
  • Author
    Posts
    • February 17, 2020 at 12:01 pm #19215
      Marta Ribeiro
      Keymaster

      Overall, first-line use of Genentech’s Ocrevus for MS patients has remained stable through 2019 compared to 2018, according to Spherix Global Insights. Read more here.

      What do you think of this information?

  • Author
    Posts
Viewing 0 reply threads
  • You must be logged in to reply to this topic.

Search forums

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Search in posts
Search in pages

Who’s Online

There are no users currently online

Members

US Hospitals Are Now Required to List Service Prices. But Does That Help?

BioNews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: [email protected]
Phone: 1-800-936-1363

Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2017-2022 All rights reserved.

©2022 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account